SEC-sourced researchBeta
VNDA
Vanda Pharmaceuticals Inc.
Company comparison ↗
Data passport
- CIK
- 0001347178
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Feb 12, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 192,640,000.0000 | Feb 12, 2026 |
| December 2024 | 198,772,000.0000 | Feb 12, 2026 |
| December 2025 | 216,105,000.0000 | Feb 12, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 216,105,000.0000 | -220,474,000.0000 | -109,442,000.0000 | 488,948,000.0000 | 161,762,000.0000 | Feb 12, 2026 |
| December 2024 | 198,772,000.0000 | -18,900,000.0000 | -15,757,000.0000 | 656,204,000.0000 | 117,658,000.0000 | Feb 12, 2026 |
| December 2023 | 192,640,000.0000 | 2,509,000.0000 | 12,801,000.0000 | — | — | Feb 12, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $216.11M | December 2025 | Feb 12, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $198.77M | December 2024 | Feb 12, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$220.47M | December 2025 | Feb 12, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$109.44M | December 2025 | Feb 12, 2026 | 10-K |
| Total assetsAssets | $488.95M | December 2025 | Feb 12, 2026 | 10-K |
| Total liabilitiesLiabilities | $161.76M | December 2025 | Feb 12, 2026 | 10-K |